Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:36:17 EDT Tue 15 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:SNDX
- SYNDAX PHARMACEUTICALS INC -
http://www.sandstormresources.com
17:36:17 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
SNDX
- Q
0.4
8.79
·
10.05
0.1
9.21
-0.64
-6.5
1,709.8
15,238
11,743
9.90
10.02
9.15
25.06 8.58
16:24:27
Jul 02
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 11743
More trades...
Time ET
Ex
Price
Change
Volume
16:24:27
Q
9.21
-0.64
2
16:04:06
Q
9.21
-0.64
1
16:04:05
Q
9.21
-0.64
1
16:04:03
Q
9.21
-0.64
1
16:02:38
Q
9.21
-0.64
2,017
16:02:38
Q
9.21
-0.64
2,325
16:02:28
Q
9.21
-0.64
801
16:02:10
Q
9.21
-0.64
192
16:01:45
Q
9.21
-0.64
2,061
16:01:35
Q
9.21
-0.64
1,844
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-07-02 16:01
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-06-24 16:01
U:SNDX
News Release
200
Syndax Announces FDA Priority Review of sNDA for Revuforj(TM) (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
2025-06-12 12:02
U:SNDX
News Release
200
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
2025-06-12 07:00
U:SNDX
News Release
200
Syndax Presents New Revuforj(TM) (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
2025-06-05 16:01
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-05-29 07:00
U:SNDX
News Release
200
Syndax Announces Participation in June Investor Conferences
2025-05-14 09:30
U:SNDX
News Release
200
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj(TM) (revumenib) and Niktimvo(TM) (axatilimab-csfr)
2025-05-12 16:01
U:SNDX
News Release
200
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
2025-05-08 07:00
U:SNDX
News Release
200
Syndax Announces Participation in May Investor Conferences
2025-05-07 16:01
U:SNDX
News Release
200
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
2025-05-05 16:01
U:SNDX
News Release
200
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-02 16:05
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-04-28 07:00
U:SNDX
News Release
200
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
2025-04-04 16:05
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-04-02 07:00
U:SNDX
News Release
200
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
2025-03-05 16:05
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-03-03 07:01
U:SNDX
News Release
200
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-25 07:00
U:SNDX
News Release
200
Syndax Announces Participation in March Investor Conferences
2025-02-24 07:00
U:SNDX
News Release
200
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
2025-02-04 16:05
U:SNDX
News Release
200
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)